ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2017
Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rehabilitation in patients with lymphoma: An overview of Systematic Reviews.Journal of rehabilitation medicine · 2021Pooled it
- A Novel Plasma Biomarker hsa_circ_0080018 Drives DLBCL Progression via M2 Polarization of Tumor-Associated Macrophages.Cancer science · 2026Article
- Real-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards.BMC cancer · 2026Article
- Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities.Frontiers in oncology · 2026Review
- Cost-effectiveness and budget impact of covering Burkitt lymphoma in children under Ghana's National Health Insurance Scheme.Cost effectiveness and resource allocation : C/E · 2025Article
- Defining primary refractory large B-cell lymphoma.Blood advances · 2024Article
- Choosing needles wisely: 19-G conventional vs. Franseen needles in endoscopic ultrasound-guided fine-needle aspiration for malignant lymphoma diagnosis and classification.Clinical endoscopy · 2024Article
- Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.Blood cancer journal · 2024Article
- Declining incidence and improving survival of ocular and orbital lymphomas in the US between 1995 and 2018.Scientific reports · 2024Article
- Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences.Drugs in context · 2024Article
- Editorial for theInternational journal of molecular sciences · 2023Article
- Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma.Journal of rehabilitation medicine · 2023Article
- The Use of Human Tissues for Research: What Investigators Need to Know.Alternatives to laboratory animals : ATLA · 2022Article
- Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features.Cancers · 2021Review
- Review
- Review
- An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach.Cancers · 2021Review
- MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of FasL in M1 macrophages.Journal of experimental & clinical cancer research : CR · 2020Article
- XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.Journal of hematology & oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Improved delineation of lymphoid malignancy biology has prompted refinement of the 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid tumors with a new framework introduced in 2016. This knowledge has provided valuable insights regarding management. Early clonal proliferations have been set apart given their limited potential for malignant dissemination. Increasing knowledge of molecular drivers of aggressive lymphomas has allowed subclassification and opportunity for clinical investigations to personalize therapy. New insights into T-cell pathophysiology has allowed grouping based on shared molecular and cellular features. This article will summarize the key changes in terms of diagnosis and histopathologic definitions, the impact of these changes on clinical management, and the challenges of future research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.